Catalyst Brief

← Calendar

Readoutin 14d

Shanghai JMT-Bio Inc. — KN026

Phase 3 primary completion: A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer.

Date
Dec 2026
Type
Readout
Indication
Early or Locally Advanced HER2-positive Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.